Anbio Biotechnology
Company Profile
Business description
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Contact
Friedrich-Ebert-Anlage 35-37
Frankfurt am MainHE60327
DEUT: +49 69870039170
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
27
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 7,981.76 | 5.73 | -0.07% |
| DAX 40 | 24,400.65 | 92.73 | 0.38% |
| Dow JONES (US) | 49,501.07 | 185.05 | -0.37% |
| FTSE 100 | 10,330.55 | 6.80 | 0.07% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,890.54 | 200.20 | -0.77% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,367.95 | 35.10 | -0.47% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |